Transitioning from Insulin to DDP-4 Inhibitors for Type 2 Diabetes

Dipeptidyl-peptidase 4 (DPP-4) inhibitors are a relatively new treatment regimen for Type II Diabetes Mellitus (T2DM) and are associated with less hypoglycemia than insulin. There are no published data regarding the effects of these drugs on insulin therapy. This case series presents findings from a cohort of older adults on insulin who received DPP-4 treatment with the intention of discontinuing insulin, if possible.